
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: 001-35892

GW PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

Sovereign House, Vision Park
Chivers Way, Histon
Cambridge, CB24 9BZ
United Kingdom
Tel: +44 1223 266800

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Ordinary Shares, par value £0.001 per share ("Ordinary Shares")
American Depositary Shares, each representing 12 Ordinary Shares ("ADSs")
(Title of each class of securities covered by this Form)

None.
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>
Rule 15d-22(b)	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date:

Ordinary Shares	3
ADSs	Less than 300

Pursuant to the requirements of the Securities Exchange Act of 1934, GW Pharmaceuticals plc has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: May 17, 2021

GW PHARMACEUTICALS PLC,

by

/s/ Douglass B. Snyder

Name: Douglass B. Snyder

Title: Chief Legal Officer
